Erik Hett, Ph.D., MPH

Erik Hett is the Chief Technology Officer of Sonata Therapeutics. As a cellular and chemical biologist, Erik brings over 20 years of experience to Sonata, building novel platforms that deliver robust hits and molecular insights. At Sonata, he is leading the design and development of the company’s therapeutics discovery platform.

Previously, Erik served in various leadership positions at Merck. Most recently, he was the Head of Experimental and Chemical Biology at Merck’s Exploratory Sciences Center, where he led teams of scientists in chemical biology, proteomics, metabolomics, cell assay development, bioengineering and chemistry. Prior to Merck, he served as the Team Leader in Chemical Biology at Biogen, where he led the development of novel approaches for high-value small molecule targets. Erik also served as the Principal Scientist of Chemical Biology at Pfizer.

Erik received his MPH from the Yale School of Public Health and his Ph.D. from Harvard University.